A5102816519- HIV/AIDS Research and Interventions
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- HIV, Drug Use, Sexual Risk
- HIV-related health complications and treatments
- Adolescent Sexual and Reproductive Health
- Pneumocystis jirovecii pneumonia detection and treatment
- Tuberculosis Research and Epidemiology
- Sex work and related issues
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- COVID-19 Clinical Research Studies
- Diagnosis and treatment of tuberculosis
- Hepatitis B Virus Studies
- Hepatitis C virus research
- Viral-associated cancers and disorders
- Reproductive tract infections research
- Parvovirus B19 Infection Studies
- Global Maternal and Child Health
- HIV/AIDS Impact and Responses
- Vaccine Coverage and Hesitancy
- Infectious Diseases and Tuberculosis
- Viral gastroenteritis research and epidemiology
- Biochemical and Molecular Research
- Syphilis Diagnosis and Treatment
Universidade Federal do Rio de Janeiro
2014-2024
Universidade Federal de São Paulo
2022-2023
Financiadora de Estudos e Projetos
2023
Universidade de São Paulo
2022
Universidade Federal do Estado do Rio de Janeiro
2012-2016
Chiang Mai University
2016
Fundación Huésped
2011
Royal Perth Hospital
2011
Murdoch University
2011
Hospital Universitário Clementino Fraga Filho
1999-2010
PrEP drug concentrations associated with ≥90% reduction in HIV acquisition men who have sex are achieved daily dosing.
Aims: To compare the gender distribution of HIV-infected adults receiving highly active antiretroviral treatment (HAART) in resource-constrained settings with estimates HIV infection; to describe clinical characteristics women and men HAART. Methods: The Antiretroviral Therapy Lower-Income Countries, ART-LINC Collaboration is a network clinics providing HAART Africa, Latin America, Asia. We compared UNAIDS data on infection proportions Collaboration. Results: Twenty-nine centers 13 countries...
To describe temporal trends in baseline clinical characteristics, initial treatment regimens and monitoring of patients starting antiretroviral therapy (ART) resource-limited settings.We analysed data from 17 ART programmes 12 countries sub-Saharan Africa, South America Asia. Patients aged 16 years or older with documented date start highly active (HAART) were included. Data by calculating medians, interquartile ranges (IQR) percentages regions time periods. Not all centres provided for 2006...
Background: Little is known globally about the perspectives of people living with HIV/AIDS (PLWHA) on perceived HIV-related stigma and its consequences. Methods: Cross-sectional study (January-March 2010) among PLWHA (N = 2035) using a standardized questionnaire. Findings: Thirty-seven percent respondents reported loneliness as result their HIV status. Depression was by 27%. While 96% disclosing status to at least 1 person, 17% patients who being in long-term sexual relationship had not...
Tenofovir disoproxil fumarate (TDF) pre-exposure prophylaxis decreases sexual acquisition of HIV infection. We sought to evaluate the renal safety TDF in HIV-uninfected persons.The Iniciativa Profilaxis Pre-Exposición (iPrEx) study randomly assigned 2499 HIV-seronegative men and transgender women who have sex with (MSM) receive oral daily coformulated emtricitabine (FTC/TDF) or placebo. Serum creatinine phosphorus during randomized treatment after discontinuation were measured, clearance...
This observational study assessed the effect of combination antiretroviral therapy on risk tuberculosis among 255 patients with human immunodeficiency virus (HIV) infection and advanced who were living in an area Brazil a high incidence tuberculosis. The use highly active regions prevalence coinfection HIV Mycobacterium may contribute lower
Treatment of latent tuberculosis (TB) infection with weekly rifapentine and isoniazid is a potentially effective alternative to current therapies.To compare the efficacy rifapentine/isoniazid daily rifampin/pyrazinamide in preventing TB household contacts patients pulmonary Brazil.Contacts were randomized 900 mg/isoniazid mg once for 12 wk or rifampin 450-600 mg/pyrazinamide 750-1,500 8 followed at least 2 yr.TB rates, adverse events, adherence therapy.A total 399 enrolled, 206 arm 193 arm....
Health-related quality of life (HRQL) is an important outcome in HIV/AIDS infection and treatment. However, most existing HIV-HRQL instruments miss issues (eg, sleeping problems, lipodystrophy). They were developed before highly active antiretroviral therapy (pre-HAART), a single language. We sought to develop contemporary instrument (PROQOL-HIV) multiple languages that accounts for HAART treatment side effects. This article details the 3-stage content validation phase PROQOL-HIV.In stage 1,...
Adherence to pre-exposure prophylaxis (PrEP) is critical for efficacy. Antiretroviral concentrations are an objective measure of PrEP use and correlate with Understanding patterns correlates drug detection can identify populations at risk nonadherence inform design adherence interventions.Blood antiretroviral were assessed among active arm participants in iPrEx, a randomized placebo-controlled trial emtricitabine/tenofovir men who have sex transgender women 6 countries. We evaluated rates...
Abstract Background The Strategic Timing of AntiRetroviral Treatment (START) trial demonstrated that immediate (at CD4+ >500 cells/µL) vs deferred (to <350 cells/µL or AIDS) antiretroviral therapy (ART) initiation reduced risk for AIDS and serious non-AIDS (SNA). We investigated associations inflammation, coagulation, vascular injury biomarkers with AIDS, SNA death, the effect ART initiation. Methods Biomarkers were measured from stored plasma prior to randomization at month 8....
Abstract Background Since January 2017, the recommended first-line antiretroviral regimen in Brazil is fixed-dose combination of tenofovir plus lamivudine with dolutegravir (TL + D). According to literature, integrase resistance-associated mutations (INRAMs) are rarely found upon virologic failure two nucleoside reverse transcriptase inhibitors. We evaluated HIV genotypic resistance profile patients referred for genotyping public health system who failed TL D after at least six months...
To examine the accuracy of World Health Organization immunological criteria for virological failure antiretroviral treatment.Analysis 10 treatment programmes in Africa and South America that monitor both CD4 cell counts HIV-1 viral load. Adult patients with at least two load measurements between month 6 18 after starting a non-nucleoside reverse transcriptase inhibitor-based regimen were included. WHO include persistently <100 cells/microl, fall below baseline count, or >50% from peak value....
Background: Although nearly 2 million people live with HIV in Latin America and the Caribbean, mortality rates after initiation of highly active antiretroviral therapy (HAART) have not been well described. Methods: Five thousand one hundred fifty-two HIV-infected, antiretroviral-naive adults from clinics Argentina, Brazil, Chile, Haiti, Honduras, Mexico, Peru starting HAART during 1996-2007 were included. First-year their association demographics, regimen, baseline CD4, clinical stage...
Summary Objective To assess the outcome of patients who experienced treatment failure with antiretrovirals in sub‐Saharan Africa. Methods Analysis 11 antiretroviral therapy (ART) programmes World Health Organization (WHO) criteria were used to define failure. All ART‐naive aged ≥16 started a non‐nucleoside reverse transcriptase inhibitor (NNRTI)‐based regimen and had at least 6 months follow‐up eligible. For each patient switched second‐line regimen, 10 matched remained on non‐failing...
Objectives The magnitude of HIV viral rebound following ART cessation has consequences for clinical outcome and onward transmission. We compared plasma load (pVL) after stopping initiated in primary (PHI) chronic infection (CHI). Design Two populations with protocol-indicated from SPARTAC (PHI, n = 182) SMART (CHI, 1450) trials. Methods Time pVL to reach pre-ART levels was assessed PHI using survival analysis. Differences between CHI 4 weeks were examined linear logistic regression. slopes...
Although significant progress has been made, the latest data from low- and middle-income countries show substantial gaps in reaching third "90%" (viral suppression) of UNAIDS 90-90-90 goals, especially among vulnerable key populations. This article discusses critical promising, evidence-based solutions. There is no simple and/or single approach to achieve last 90%. will require multifaceted, scalable strategies that engage people living with human immunodeficiency virus, motivate long-term...
For people with HIV and CD4+ counts >500 cells/mm3, early initiation of antiretroviral therapy (ART) reduces serious AIDS non-AIDS (SNA) risk compared deferral treatment until are <350 cells/mm3. Whether excess SNA persists once ART is initiated for those who defer uncertain.The Strategic Timing AntiRetroviral Treatment (START) trial, as previously reported, randomly assigned 4684 ART-naive HIV-positive adults .500 cells/mm3 to immediate after random assignment (n = 2325) or deferred (n=...
Background HAART rollout in Latin America and the Caribbean has increased from approximately 210,000 2003 to 390,000 patients 2007, covering 62% (51%–70%) of eligible patients, with considerable variation among countries. No multi-cohort study examined rates reasons for change initial this region. Methodology Antiretroviral-naïve > = 18 years who started between 1996 2007 had at least one follow-up visit sites Argentina, Brazil, Chile, Haiti, Honduras, Mexico Peru were included. Time...